Immunologically active fragments of toxoplasma gondii

Patent metadata

Field	Value
Publication number	US-12156906-B2
Application number	US-202017636743-A
Country	US
Kind code	B2
Filing date	Aug 19, 2020
Priority date	Aug 19, 2019
Publication date	Dec 3, 2024
Grant date	Dec 3, 2024

Abstract

T. gondii proteins MIC1 and MIC4 are components of excretory/secretory antigens (ESA) that elicit delayed type hypersensitivity (DTH) responses in infected animals. These antigens are capable of inducing IFN-g secretion by splenic T cells (ELISPOT assay), stimulating T cells to produce cytokines that recruit inflammatory monocytes and neutrophils resulting in a positive luminol test (luminol ear assay), and eliciting a positive skin test in the guinea pig.

First claim

What is claimed is:

1. A composition comprising an antigen consisting of the amino acid sequence set forth in SEQ ID NO: 3.

2. The composition of claim 1 , further comprising a protein fragment of MIC4 comprising the amino acid sequence set forth in any one of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 14.

3. The composition of claim 1 , wherein the antigen has less than 0.1 EU/ml of lipopolysaccharide.

4. The composition of claim 1 , wherein the antigen is in admixture with a distinct purified protein fragment of a Toxoplasma gondii excretory secretory antigen.

5. A kit comprising (a) the composition of claim 1 ;
and (b) an applicator device for administration of the composition to a subject.

6. The kit of claim 5 , wherein the composition is separately packaged within the kit.

7. The kit of claim 5 , wherein the applicator device is separately packaged within the kit.

8. The kit of claim 5 , wherein the applicator device comprises a patch.

9. The kit of claim 5 , wherein the applicator device comprises a needle.

10. The kit of claim 5 , wherein the applicator device comprises a prong.

11. A method of delivering a composition comprising the composition of claim 1 to a subject, the method comprising:
contacting an applicator device which is loaded with the composition with skin of the subject, whereby the antigen is delivered to the skin of the subject.

12. The method of claim 11 , wherein the applicator device comprises a patch.

13. The method of claim 11 , wherein the applicator device comprises a needle.

14. The method of claim 11 , wherein the applicator device comprises a prong.

15. The method of claim 11 , wherein the applicator device delivers the composition percutaneously.

Assignees

• Washington University St Louis

Inventors

• Sibley Laurence David
• Saraav Iti
• Wang Qiuling
• Savari Dhason Mary

Classifications

• C07K16/20 Primary

  from protozoa · CPC title

• C07K14/45

  Toxoplasma · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title

• A61P33/02

  Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title